id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2016-E-2379-0007,FDA,FDA-2016-E-2379,Letter from FDA CDER to U.S. Patent and Trademark Office,Other,Letter(s),2019-07-08T04:00:00Z,2019,7,2019-07-08T04:00:00Z,,2019-07-08T18:12:36Z,,0,0,0900006483d684c6
FDA-2016-E-2379-0006,FDA,FDA-2016-E-2379,"Determination of Regulatory Review Period for Purposes of Patent
Extension; IDELVION",Notice,Determinations,2018-02-09T05:00:00Z,2018,2,2018-02-09T05:00:00Z,2018-04-11T03:59:59Z,2018-02-12T16:33:53Z,2018-02666,0,0,0900006482f05fa6
FDA-2016-E-2379-0005,FDA,FDA-2016-E-2379,Letter from FDA CDER to the U.S. Patent and Trademark Office,Other,Letter(s),2017-06-07T04:00:00Z,2017,6,2017-06-07T04:00:00Z,,2017-06-07T16:30:38Z,,0,0,09000064826a2082
FDA-2016-E-2379-0004,FDA,FDA-2016-E-2379,Letter from U.S. Patent and Trademark Office to CDER,Other,Letter(s),2016-12-27T05:00:00Z,2016,12,2016-12-27T05:00:00Z,,2016-12-27T18:16:55Z,,0,0,0900006482438391
FDA-2016-E-2379-0003,FDA,FDA-2016-E-2379,Letter from FDA CDER to the U.S. Patent and Trademark Office,Other,Letter(s),2016-08-29T04:00:00Z,2016,8,2016-08-29T04:00:00Z,,2016-08-29T14:49:52Z,,0,0,09000064821a8f90
FDA-2016-E-2379-0002,FDA,FDA-2016-E-2379,Letter from U.S. Patent and Trademark Office,Other,Letter(s),2016-08-03T04:00:00Z,2016,8,2016-08-03T04:00:00Z,,2016-08-03T15:54:19Z,,0,0,090000648214fef2
FDA-2016-E-2379-0001,FDA,FDA-2016-E-2379,"Patent Extension Application from Finnegan, Henderson, Farabow, Garrett & Dunner, LLP (on behalf of CSL Behring GmbH)",Other,Letter(s),2016-08-02T04:00:00Z,2016,8,2016-08-02T04:00:00Z,,2016-08-03T01:20:08Z,,0,0,090000648214feee